DelMar Pharmaceuticals Profile

Performance

   

Odds of Distress

94%94%
Check how we calculate scores
Equity ratings for DelMar Pharmaceuticals are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting June 21, 2019 and ending today September 19, 2019. Click here to learn more.

DelMar Pharmaceuticals Summary

DelMar Pharmaceuticals (DMPI) is traded on BATS Exchange in USA. It is located in 12707 High Bluff Drive and employs 2 people. DelMar Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with current market capitalization of 7.51M. DelMar Pharmaceuticals conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 8.73M outstanding shares of which 443.02K shares are currently shorted by private and institutional investors with about 0.33 trading days to cover. DELMAR PHARMA currently holds about 3.72M in cash with (6.33M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Check DelMar Pharmaceuticals Probability Of Bankruptcy

Ownership Allocation (%)

DelMar Pharmaceuticals Target Price Odds Analysis

Odds Below 0.5854HorizonTargetOdds Above 0.5854
7.64%30 days 0.59 92.34%
Based on normal probability distribution, the odds of DelMar Pharmaceuticals to move above current price in 30 days from now is about 92.34% (This DelMar Pharmaceuticals probability density function shows the probability of DelMar Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

DelMar Pharmaceuticals Top Holders

DelMar Pharmaceuticals Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Virtu Financial LlcCommon Shares63.9 K82 K
Ladenburg Thalmann Financial Services IncCommon Shares4 K5 K
View DelMar Pharmaceuticals Diagnostics

DelMar Pharmaceuticals Income Statement Over Time

Consolidated Income    Earning Before Interest and Taxes EBIT    Net Income    

DelMar Pharmaceuticals Key Fundamentals

DelMar Pharmaceuticals Against Markets

DelMar Pharmaceuticals Vital Trading Data

DelMar Pharmaceuticals, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients who have failed to respond to modern therapy. DelMar Pharmaceuticals, Inc. was founded in 2009 and is headquartered in San Diego, California. DelMar Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 2 people. more
Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
DelMar Pharmaceuticals SEC Filings
DelMar Pharmaceuticals SEC Filings
Security & Exchange Commission EDGAR ReportsView All
NameDelMar Pharmaceuticals
President CEO, DirectorJeffrey BachaView All
Thematic Classification
Currently Active Investing Idea
  Pharmaceutical Products
View All
Analyst Consensus
Piotroski F Score
Macroaxis Advice
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
LocationBritish Columbia Canada
Business Address12707 High Bluff Drive
ExchangeBATS Exchange
CUSIP247078108
SectorHealthcare
IndustryBiotechnology
BenchmarkDOW
Websitewww.delmarpharma.com
Phone858 350 4364
CurrencyUSD - US Dollar
Next Fiscal Year EndJune 30, 2021
Most Recent QuarterJune 30, 2019
Last Fiscal Year EndJune 30, 2019
Date Short InterestAugust 15, 2019

DelMar Pharmaceuticals Corporate Directors

John Bell Independent Director
William Garner Director
Erich Mohr Independent Director
Additionally see Investing Opportunities. Please also try Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Search macroaxis.com